Physicians’ and patients’ thoughts on the prostate cancer screening test are changing, with many taking a more cautious approach to the test and what it might mean.
Overall death rates from cancer declined from 2000 through 2009 in the United States, maintaining a trend seen since the early 1990s. Among men, the overall rate of cancer incidence fell by an average of 0.6 percent annually from 2000 through 2009. Cancer incidence rates were stable among women during the same time period and rose by 0.6 percent per year among children.
Ask experts to predict the future of cancer screening, and you’ll get a range of answers. But all would agree that we need better ways to detect cancers early in the course of disease, and these new tools should improve on the benefits of screening while limiting the harms.
When it comes to prostate cancer, there’s a lot of confusion about how to prevent it, find it early and the best way – or even whether – to treat it. Here two scientists at Fred Hutchinson Cancer Research Center to help men separate fact from fiction.
What do you do when you’ve finished treatment?How do you coordinate your ongoing care with your primary care doc? How do you keep track of your medical records and get the right information to the right people about what you’ve been through? Gilda’s Club has some answers.
Deaths from cancer in the U.S. declined from 1999 to 2008, maintaining a trend seen since the early 1990s. Mortality fell for most cancer types, including the four most common types of cancer in the United States — lung, colorectal, breast, and prostate –, although the rate of decline varied by cancer type and across racial and ethnic groups.
Men who underwent annual prostate cancer screening with prostate-specific antigen testing and digital rectal examination had a 12 percent higher incidence of prostate cancer than men in the control group but the same rate of death from the disease.
The influential U.S. Preventive Services Task Force finds that routine PSA testing does men more harm than good.
Are older patients being over tested? There is little evidence the elderly benefit from colon, breast and prostate cancer screening — and considerable risk.
Robotic prostatectomy proliferated quickly, but what it means for patients and the health care system, is still a matter of study and debate.
Sometimes, delaying treatment while regularly monitoring the progress of a disease — a strategy called “watchful waiting” — may be better than starting treatment right away.
Screening tests that diagnose illnesses early may actually cause more harm than good, a team of Dartmouth medical researchers argue in a new book. Michelle Andrews interview the authors.
For men with prostate cancer that grows slowly, the treatments may cause more harm than good.
The treatment is an novel immune therapy in which a patient’s immune cells are stimulated to attack prostate cancer cells more aggressively.
FDA weighs Seattle company’s cancer vaccine. Officials investigate reports of H1N1 vaccine side effects. Con artists take advantage of confusion over health reform.